Vor Biopharma Inc. (VOR)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Vor Biopharma Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 19.11 | 20.00 | 18.61 | 19.88 | 555,466 |
| Nov 5, 2026 | 20.08 | 20.08 | 18.33 | 18.66 | 636,355 |
| Nov 4, 2026 | 20.63 | 20.70 | 19.47 | 20.12 | 415,418 |
| Nov 3, 2026 | 19.45 | 20.64 | 18.93 | 19.86 | 906,174 |
| Nov 2, 2026 | 19.71 | 20.00 | 18.84 | 19.25 | 624,088 |
| Oct 30, 2026 | 19.98 | 20.47 | 19.37 | 19.68 | 759,596 |
| Oct 29, 2026 | 20.80 | 21.74 | 20.66 | 20.91 | 968,249 |
| Oct 28, 2026 | 19.50 | 20.81 | 19.27 | 20.65 | 1,013,832 |
| Oct 27, 2026 | 18.36 | 19.56 | 18.02 | 19.54 | 770,826 |
| Oct 26, 2026 | 18.33 | 18.44 | 17.70 | 18.33 | 470,344 |
| Oct 23, 2026 | 18.67 | 18.81 | 17.95 | 18.26 | 720,971 |
| Oct 22, 2026 | 18.87 | 19.44 | 18.65 | 18.94 | 723,516 |
| Oct 21, 2026 | 19.18 | 19.79 | 18.79 | 18.94 | 817,612 |
| Oct 20, 2026 | 18.06 | 19.55 | 18.00 | 19.03 | 795,999 |
| Oct 19, 2026 | 18.37 | 18.72 | 17.73 | 18.04 | 724,817 |
| Oct 16, 2026 | 19.45 | 19.45 | 18.00 | 18.03 | 735,159 |
| Oct 15, 2026 | 18.85 | 20.25 | 18.78 | 19.34 | 696,787 |
| Oct 14, 2026 | 18.79 | 19.74 | 18.55 | 18.75 | 927,175 |
| Oct 13, 2026 | 19.50 | 19.95 | 18.98 | 19.06 | 949,441 |
| Oct 12, 2026 | 19.79 | 20.52 | 19.55 | 19.80 | 867,440 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Sokolove Jeremy Brett | Chief Medical Officer | Automatic Sell | 1.9K | $36.9K | Nov 2, 2026 |
 RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | 500 | -- | Oct 2, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | 500 | $6.4K | Oct 2, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | 1.5K | -- | Aug 24, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Option Exercise | 1.5K | $5.6K | Aug 24, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sale | 213 | $4.2K | Jul 16, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
RA Capital Management, L.P. · also on 13F· joint filing· may incl. warrants· filed Jul 2026 | 12.9M | 21.1% | 13D |
ForGrowth III PA B.V. · may incl. warrants· filed Dec 2025 | 10.2M | 10.0% as filed | 13D |
FMR LLC · net of 13F· joint filing· may incl. warrants· filed Nov 2026 | 6.3M | 10.3% | 13G |
Venrock Healthcare Capital Partners III, L.P. · joint filing· may incl. warrants· reaffirmed 13F Aug 2026 | 5.7M | 9.2% | 13G |
TCG Crossover Management, LLC | 5.7M | 9.2% | 13F |
Verve Capital Limited · may incl. warrants· filed May 2026 | 5.0M | 8.1% | 13G |
FMR LLC | 4.9M | 8.0% | 13F |
FCPM III SERVICES B.V. | 4.1M | 6.7% | 13F |
BlackRock, Inc. | 3.5M | 5.6% | 13F |
Venrock Adviser, LLC | 3.0M | 5.0% | 13F |
Insiders
- Sokolove Jeremy BrettChief Medical Officer
- RA CAPITAL MANAGEMENT, L.P.10% Owner
- ZACCARDELLI DAVIDDirector
- Namouni FouadDirector
- Detheux MichelDirector
- Levin Andrew DavidDirector
- Beckman DaniellaDirector
- Joustra WouterDirector
- Kalir ErezDirector
- Cumbo AlexanderDirector
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer.
Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells.
The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
based on 61.43M shares outstanding
US30d Avg
753.96K
60d Avg
1.06M
90d Avg
948.04K